IUB C3A Pilot Project Core

试点项目核心摘要 大麻、大麻素和成瘾(C3A)试点项目核心将建立一个试点项目 旨在每年支持2至4个新项目的计划。试点项目核心圆周率是诺伯特·哈乔斯教授， 他是神经科学的吉尔教授。其目标是支持和鼓励创新和探索 来自受训者的项目，并建立调查人员，探索与药物滥用有关的新研究路线。 试点项目将每年向C3A附属公司及其受训人员征求意见。我们预计其中一些 试点项目的建议书将来自我们的NIDA-T32，DA024628支持的学员。每项提案都将是 由外部咨询委员会2名成员和内部咨询委员会2名成员审查。 提案将按以下优先事项排序：1.支持年轻的调查员/新入职的调查员 上瘾领域。2.支持历来在药物滥用研究中任职人数不足的群体。3.一个项目 将最大限度地受益于访问BLM或MSPM核心。4.获取NIDA拨款的初步数据 申请。5.包括高风险/高支出的组成部分。以下提案将获得较低的优先级 只是对正在进行的资助研究进行补充。所有申请者将收到对他们的建议的反馈，并将被 在C3A的后续申请中提供由C3A PI或附属公司指导的机会 外部机构。成功申请者将被指派一名核心工作人员来优化实验 利用相关核心(S)的技术能力进行设计，并与IUB C3A中心匹配 附属机构在药物滥用领域提供指导。获奖者将至少展示他们的作品三次 参加每月的C3A研究会议，还有一次参加外部顾问委员会。还将提交一份总结报告 在项目完成时做好准备。 根据这些标准，我们选择了两个项目作为本P30的初次提交。试点项目1有 是由加布里埃尔·纳提出的，他是一名研究生，与乔纳森·克里斯托博士合作，他是哈佛大学教务长教授 布卢明顿国际机场。Nah先生的项目使用一个老鼠模型来检查青少年接触THC对 轻度创伤性脑损伤后的脂类、解剖学、分子和认知改变，并将使用这两种方法 脂质组学和成像核心。试点项目2是由中心附属机构Shanna Babalonis博士提出的， 作为肯塔基大学的助理教授，研究人类人群中的多种药物使用。Dr。 Babalonis的项目将使用脂质组学核心来检查血浆脂质体和植物大麻素水平 在有和没有吸入性大麻暴露的受控环境中使用阿片类药物。这两个试点项目相遇 试点项目核心在以下方面的目标：项目1支持非裔美国毕业生 学生致力于一个重要的问题，解决以前使用药物对创伤后遗症的影响 脑部受伤。项目2支持一名早期调查员审查大麻素之间的相互作用， 临床人群中的脂类和阿片类药物。

Pilot Project Core Abstract The IUB Center for Cannabis, Cannabinoids and Addiction (C3A) Pilot Project Core will establish a pilot project program designed to support 2 to 4 new projects/year. The Pilot Project Core PI is Professor Norbert Hájos, who holds a Gill Chair of Neuroscience. Its goal is to support and encourage innovative and exploratory projects from trainees and establish investigators exploring new lines of research related to substance abuse. Pilot projects will be solicited annually from C3A Affiliates and their trainees. We anticipate that some of these pilot project proposals will come from trainees supported by our NIDA-T32, DA024628. Each proposal will be reviewed by 2 members of the External Advisory Board and 2 members of the Internal Advisory Board. Proposals will be ranked by the following priorities: 1. Support of young investigators/investigators new to the addiction field. 2. Support of groups historically underrepresented in drug abuse research. 3. A project that will maximally benefit from access to either the BLM or MSPM cores. 4. Obtain preliminary data for NIDA grant application. 5. Includes a component of high risk/high payout. Low priority will be given to proposals that merely supplement ongoing funded research. All applicants will receive feedback on their proposals and will be offered the opportunity to be mentored by a C3A PI or Affiliate in subsequent applications to the C3A or external agencies. Successful applicants will be assigned a Core staff member to optimize experimental design with the technical capabilities of the relevant core(s) utilized and matched with a IUB C3A Center Affiliate to provide guidance in the substance abuse field. Awardees will present their work at least three times to the monthly C3A research meetings and once to the external advisory board. A summary report will also be prepared when the project is completed. Based on these criteria, we have chosen two projects for the initial submission of this P30. Pilot Project 1 has been proposed by Gabriel Nah, a graduate student working with Dr. Jonathan Crystal, a Provost Professor at IU Bloomington. Mr. Nah’s project uses a rat model to examine the impact of adolescent THC exposure on the lipidomic, anatomical, molecular, and cognitive changes following mild traumatic brain injury and will use both the lipidomics and imaging cores. Pilot Project 2 has been proposed by Center Affiliate, Dr. Shanna Babalonis, as assistant professor at the University of Kentucky studying multi-drug use in human populations. Dr. Babalonis’ project will use the lipidomics core to examine the plasma lipidome and phytocannabinoid levels in opioid users in a controlled setting with and without inhaled cannabis exposure. These two pilot projects meet the goals of the Pilot Project Core in the following ways: Project 1 supports an African American graduate student working on a significant question addressing the impact of prior drug use on the sequelae of traumatic brain injury. Project 2 supports an early-stage investigator examining the interactions between cannabinoids, lipids, and opioids in a clinical population.